Boston Partners Has $24 Million Position in Halozyme Therapeutics, Inc. $HALO

Boston Partners lifted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.9% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 449,366 shares of the biopharmaceutical company’s stock after purchasing an additional 33,041 shares during the period. Boston Partners owned 0.36% of Halozyme Therapeutics worth $23,999,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. CWM LLC grew its holdings in Halozyme Therapeutics by 46.3% during the 1st quarter. CWM LLC now owns 1,383 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 438 shares during the period. AE Wealth Management LLC bought a new stake in shares of Halozyme Therapeutics during the 1st quarter valued at about $206,000. LPL Financial LLC grew its stake in Halozyme Therapeutics by 17.1% during the first quarter. LPL Financial LLC now owns 242,432 shares of the biopharmaceutical company’s stock worth $15,470,000 after purchasing an additional 35,429 shares during the period. Mackenzie Financial Corp grew its stake in Halozyme Therapeutics by 392.1% during the first quarter. Mackenzie Financial Corp now owns 85,609 shares of the biopharmaceutical company’s stock worth $5,463,000 after purchasing an additional 68,213 shares during the period. Finally, Harvest Fund Management Co. Ltd bought a new stake in Halozyme Therapeutics in the first quarter worth approximately $89,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have weighed in on HALO. Wall Street Zen raised shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 16th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research note on Tuesday, November 4th. JPMorgan Chase & Co. upped their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research note on Monday, October 27th. Weiss Ratings reiterated a “buy (b)” rating on shares of Halozyme Therapeutics in a report on Wednesday, November 19th. Finally, The Goldman Sachs Group raised their price objective on Halozyme Therapeutics from $54.00 to $56.00 and gave the company a “neutral” rating in a research note on Tuesday, November 18th. Seven research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $75.10.

Insider Buying and Selling

In related news, Director Bernadette Connaughton sold 2,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $68.48, for a total value of $136,960.00. Following the transaction, the director directly owned 42,952 shares in the company, valued at approximately $2,941,352.96. This represents a 4.45% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $69.13, for a total transaction of $1,382,600.00. Following the sale, the chief executive officer directly owned 733,719 shares of the company’s stock, valued at $50,721,994.47. This represents a 2.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 110,227 shares of company stock worth $8,028,955. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO opened at $71.39 on Friday. Halozyme Therapeutics, Inc. has a fifty-two week low of $46.26 and a fifty-two week high of $79.50. The firm has a 50-day moving average of $69.25 and a 200 day moving average of $63.75. The company has a debt-to-equity ratio of 4.54, a quick ratio of 7.01 and a current ratio of 8.36. The firm has a market cap of $8.39 billion, a P/E ratio of 16.34, a PEG ratio of 0.35 and a beta of 1.18.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.09. The company had revenue of $354.26 million during the quarter, compared to the consensus estimate of $339.18 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The firm’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.27 EPS. On average, research analysts expect that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.